SER-109
SERES-004
Phase 2 small_molecule completed
Quick answer
SER-109 for Clostridium Difficile is a Phase 2 program (small_molecule) at Seres Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Seres Therapeutics
- Indication
- Clostridium Difficile
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed